Celgene Corp. (CELG) News Nov 20, 2014, 6:36 p.m.
Post# of 250602
Posted On: 11/20/2014 7:05:38 PM
Celgene Corp. (CELG) News Nov 20, 2014, 6:36 p.m.
MarketWatch News on CELG
5 charts show how stock repurchases boost prices 6:00 a.m. Nov. 18, 2014 - Ophir Gottlieb
The double-edged sword of growth-stock speculation 2:30 p.m. Nov. 14, 2014 - The Trading Deck
Two biotech leaders to watch 1:13 p.m. Oct. 28, 2014 - The Trading Deck
Celgene profit up 37%, raises outlook 7:42 a.m. Oct. 23, 2014 - MarketWatch.com
Be ready to play another market surge 11:25 a.m. Sept. 19, 2014 - The Trading Deck
14 stocks loved by top-performing fund managers 5:49 a.m. Sept. 18, 2014 - Philip van Doorn
Lululemon surges; RadioShack rebounds 2:24 p.m. Sept. 11, 2014 - Sue Chang
Major U.S. benchmarks rattle cage on first support 10:06 a.m. Sept. 10, 2014 - Michael Ashbaugh
Celgene shares up on news of positive late-stage drug trial 6:42 a.m. Sept. 4, 2014 - Ciara Linnane
How retail sector sets up stocks at the end of summer 2:32 p.m. Aug. 14, 2014 - The Trading Deck
S&P 500 retests the breakdown point 10:17 a.m. Aug. 14, 2014 - Michael Ashbaugh
S&P 500 ekes out another record close: stock market live blog recap 3:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 10:44 a.m. July 24, 2014 - Russ Britt
Biogen results crush consensus 3:55 p.m. July 23, 2014 - The Trading Deck
Nasdaq needs to turn up the volume 10:59 a.m. July 17, 2014 - The Trading Deck
Bull rolls on, but opportunities start to dwindle 12:52 p.m. July 10, 2014 - The Trading Deck
Reynolds rises on buyout report; Delta gains altitude 1:25 p.m. July 9, 2014 - Sue Chang
Celgene's arthritis drug fails a test, but company's stock rises anyway 12:23 p.m. July 9, 2014 - Russ Britt
Celgene shares slump as late-stage trial misses goal 6:27 a.m. July 9, 2014 - Ciara Linnane
S&P, Dow rattle cage on uncharted territory 10:20 a.m. July 1, 2014 - Michael Ashbaugh
Other News on CELG
Agios (AGIO) Shares Up on Positive AG-120 Study Data - Analyst Blog 4:33 p.m. Today - Zacks.com
Celgene Up on Encouraging Long-Term Phase III Otezla Data - Analyst Blog 5:10 p.m. Nov. 19, 2014 - Zacks.com
Jim Cramer Explains Why Investors Win With Agios Pharmaceuticals (AGIO) 2:11 p.m. Nov. 19, 2014 - TheStreet.com
Hottest Healthcare Stocks Now – ACOR CBPO CELG AMGN 12:00 p.m. Nov. 19, 2014 - InvestorPlace.com
Cramer: Agios Pharmaceuticals' Leukemia Drug Pushing Stock 'Much Higher' 11:21 a.m. Nov. 19, 2014 - TheStreet.com
Jim Cramer's Top Stock Picks: MMM UNH CELG AMZN HD ALKS PPG 6:00 a.m. Nov. 19, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Why Running With the Bulls Is Profitable but Dangerous 8:10 p.m. Nov. 18, 2014 - TheStreet.com
Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells 6:02 p.m. Nov. 18, 2014 - TheStreet.com
Gilead's Value Without Its Hep C Franchise 4:07 p.m. Nov. 18, 2014 - Seeking Alpha
3 Stocks Reiterated As A Buy: CELG, BAC, XOM 1:29 p.m. Nov. 18, 2014 - TheStreet.com
Celgene presents Phase 3 Otezla data 10:05 a.m. Nov. 18, 2014 - Seeking Alpha
Gilead Has Been Rocked After Earnings, But I'm Looking To Buy! 12:35 p.m. Nov. 17, 2014 - Seeking Alpha
'Fast Money' Recap: Was Friday the Start of a Bull Rally in Gold? 5:00 a.m. Nov. 15, 2014 - TheStreet.com
Medical Stocks Tumble But Most Of IBD 50 Trading Well 5:47 p.m. Nov. 14, 2014 - Investors Business Daily
Biotech Stocks Hit: Stock Market To See New Leaders? 5:22 p.m. Nov. 14, 2014 - Investors Business Daily
Synageva Up on New Phase III Data on Sebelipase Alfa - Analyst Blog 3:40 p.m. Nov. 14, 2014 - Zacks.com
Sarepta Initiates Dosing for Study Evaluating Eteplirsen - Analyst Blog 5:40 p.m. Nov. 13, 2014 - Zacks.com
Sarepta Initiates Dosing for Study Evaluating Eteplirsen - Analyst Blog 5:40 p.m. Nov. 13, 2014 - Zacks.com
Ligand/Glaxo Seek EU Nod for Severe Aplastic Anemia Drug - Analyst Blog 5:00 p.m. Nov. 13, 2014 - Zacks.com
Celgene Is Up 22% Over The Past Month; What Do Technicians Think? 1:12 p.m. Nov. 13, 2014 - benzinga.com
Press Releases on CELG
Chef Michael Ferraro, the Pancreatic Cancer Action Network and Meals to Heal Team up with Celgene to Address Nutritional Needs and Challenges Faced by Pancreatic Cancer Patients and Caregivers 8:00 a.m. Today - BusinessWire - BZX
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV 4:29 p.m. Nov. 19, 2014 - Marketwired
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV 3:35 p.m. Nov. 19, 2014 - Marketwired
Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis 7:30 a.m. Nov. 18, 2014 - BusinessWire - BZX
Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases 9:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Critical Alerts For Alibaba, Bloomin' Brands, VoxelJet, 51job and Celgene Released By InvestorsObserver 9:31 a.m. Nov. 5, 2014 - PR Newswire - PRF
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress 8:30 a.m. Oct. 31, 2014 - BusinessWire - BZX
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014 7:35 a.m. Oct. 20, 2014 - BusinessWire - BZX
Technical Scrutiny on Health Care Sector Stocks - ImmunoGen, Arrowhead Research, Chimerix, Tekmira Pharma, and Celgene 9:10 a.m. Oct. 15, 2014 - PR Newswire - PRF
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene 8:30 a.m. Oct. 14, 2014 - PR Newswire - PRF
New Analyses of Oral OTEZLA® (Apremilast) Presented at EADV Show Efficacy in Difficult-to-Treat Areas of Moderate to Severe Plaque Psoriasis 8:38 a.m. Oct. 10, 2014 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis 8:37 a.m. Oct. 10, 2014 - BusinessWire - BZX
Critical Alerts For Exxon Mobil, Celgene, Verizon, Intercept Pharmaceuticals and Lockheed Martin Released By InvestorsObserver 9:31 a.m. Oct. 8, 2014 - PR Newswire - PRF
Celgene to Present Long-Term Efficacy and Safety Data on Oral OTEZLA® (apremilast) in Plaque Psoriasis and Psoriatic Arthritis at European Academy of Dermatology and Venereology Congress 7:30 a.m. Oct. 7, 2014 - BusinessWire - BZX
Regulatory Approvals, Lawsuits, Positive Study Results, Welfare Initiatives, and Technical Updates - Research Reports on Celgene, Actavis, Bristol-Myers Squibb, UnitedHealth and Vertex 9:20 a.m. Oct. 2, 2014 - PR Newswire - PRF
Celgene Corporation to Announce Third Quarter 2014 Results on October 23, 2014 8:30 a.m. Oct. 1, 2014 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Approved by the U.S. Food and Drug Administration for the Treatment of Patients with Moderate to Severe Plaque Psoriasis 3:18 p.m. Sept. 23, 2014 - BusinessWire - BZX
MarketWatch News on CELG
5 charts show how stock repurchases boost prices 6:00 a.m. Nov. 18, 2014 - Ophir Gottlieb
The double-edged sword of growth-stock speculation 2:30 p.m. Nov. 14, 2014 - The Trading Deck
Two biotech leaders to watch 1:13 p.m. Oct. 28, 2014 - The Trading Deck
Celgene profit up 37%, raises outlook 7:42 a.m. Oct. 23, 2014 - MarketWatch.com
Be ready to play another market surge 11:25 a.m. Sept. 19, 2014 - The Trading Deck
14 stocks loved by top-performing fund managers 5:49 a.m. Sept. 18, 2014 - Philip van Doorn
Lululemon surges; RadioShack rebounds 2:24 p.m. Sept. 11, 2014 - Sue Chang
Major U.S. benchmarks rattle cage on first support 10:06 a.m. Sept. 10, 2014 - Michael Ashbaugh
Celgene shares up on news of positive late-stage drug trial 6:42 a.m. Sept. 4, 2014 - Ciara Linnane
How retail sector sets up stocks at the end of summer 2:32 p.m. Aug. 14, 2014 - The Trading Deck
S&P 500 retests the breakdown point 10:17 a.m. Aug. 14, 2014 - Michael Ashbaugh
S&P 500 ekes out another record close: stock market live blog recap 3:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 10:44 a.m. July 24, 2014 - Russ Britt
Biogen results crush consensus 3:55 p.m. July 23, 2014 - The Trading Deck
Nasdaq needs to turn up the volume 10:59 a.m. July 17, 2014 - The Trading Deck
Bull rolls on, but opportunities start to dwindle 12:52 p.m. July 10, 2014 - The Trading Deck
Reynolds rises on buyout report; Delta gains altitude 1:25 p.m. July 9, 2014 - Sue Chang
Celgene's arthritis drug fails a test, but company's stock rises anyway 12:23 p.m. July 9, 2014 - Russ Britt
Celgene shares slump as late-stage trial misses goal 6:27 a.m. July 9, 2014 - Ciara Linnane
S&P, Dow rattle cage on uncharted territory 10:20 a.m. July 1, 2014 - Michael Ashbaugh
Other News on CELG
Agios (AGIO) Shares Up on Positive AG-120 Study Data - Analyst Blog 4:33 p.m. Today - Zacks.com
Celgene Up on Encouraging Long-Term Phase III Otezla Data - Analyst Blog 5:10 p.m. Nov. 19, 2014 - Zacks.com
Jim Cramer Explains Why Investors Win With Agios Pharmaceuticals (AGIO) 2:11 p.m. Nov. 19, 2014 - TheStreet.com
Hottest Healthcare Stocks Now – ACOR CBPO CELG AMGN 12:00 p.m. Nov. 19, 2014 - InvestorPlace.com
Cramer: Agios Pharmaceuticals' Leukemia Drug Pushing Stock 'Much Higher' 11:21 a.m. Nov. 19, 2014 - TheStreet.com
Jim Cramer's Top Stock Picks: MMM UNH CELG AMZN HD ALKS PPG 6:00 a.m. Nov. 19, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Why Running With the Bulls Is Profitable but Dangerous 8:10 p.m. Nov. 18, 2014 - TheStreet.com
Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells 6:02 p.m. Nov. 18, 2014 - TheStreet.com
Gilead's Value Without Its Hep C Franchise 4:07 p.m. Nov. 18, 2014 - Seeking Alpha
3 Stocks Reiterated As A Buy: CELG, BAC, XOM 1:29 p.m. Nov. 18, 2014 - TheStreet.com
Celgene presents Phase 3 Otezla data 10:05 a.m. Nov. 18, 2014 - Seeking Alpha
Gilead Has Been Rocked After Earnings, But I'm Looking To Buy! 12:35 p.m. Nov. 17, 2014 - Seeking Alpha
'Fast Money' Recap: Was Friday the Start of a Bull Rally in Gold? 5:00 a.m. Nov. 15, 2014 - TheStreet.com
Medical Stocks Tumble But Most Of IBD 50 Trading Well 5:47 p.m. Nov. 14, 2014 - Investors Business Daily
Biotech Stocks Hit: Stock Market To See New Leaders? 5:22 p.m. Nov. 14, 2014 - Investors Business Daily
Synageva Up on New Phase III Data on Sebelipase Alfa - Analyst Blog 3:40 p.m. Nov. 14, 2014 - Zacks.com
Sarepta Initiates Dosing for Study Evaluating Eteplirsen - Analyst Blog 5:40 p.m. Nov. 13, 2014 - Zacks.com
Sarepta Initiates Dosing for Study Evaluating Eteplirsen - Analyst Blog 5:40 p.m. Nov. 13, 2014 - Zacks.com
Ligand/Glaxo Seek EU Nod for Severe Aplastic Anemia Drug - Analyst Blog 5:00 p.m. Nov. 13, 2014 - Zacks.com
Celgene Is Up 22% Over The Past Month; What Do Technicians Think? 1:12 p.m. Nov. 13, 2014 - benzinga.com
Press Releases on CELG
Chef Michael Ferraro, the Pancreatic Cancer Action Network and Meals to Heal Team up with Celgene to Address Nutritional Needs and Challenges Faced by Pancreatic Cancer Patients and Caregivers 8:00 a.m. Today - BusinessWire - BZX
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV 4:29 p.m. Nov. 19, 2014 - Marketwired
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV 3:35 p.m. Nov. 19, 2014 - Marketwired
Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis 7:30 a.m. Nov. 18, 2014 - BusinessWire - BZX
Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases 9:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Critical Alerts For Alibaba, Bloomin' Brands, VoxelJet, 51job and Celgene Released By InvestorsObserver 9:31 a.m. Nov. 5, 2014 - PR Newswire - PRF
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress 8:30 a.m. Oct. 31, 2014 - BusinessWire - BZX
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014 7:35 a.m. Oct. 20, 2014 - BusinessWire - BZX
Technical Scrutiny on Health Care Sector Stocks - ImmunoGen, Arrowhead Research, Chimerix, Tekmira Pharma, and Celgene 9:10 a.m. Oct. 15, 2014 - PR Newswire - PRF
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene 8:30 a.m. Oct. 14, 2014 - PR Newswire - PRF
New Analyses of Oral OTEZLA® (Apremilast) Presented at EADV Show Efficacy in Difficult-to-Treat Areas of Moderate to Severe Plaque Psoriasis 8:38 a.m. Oct. 10, 2014 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis 8:37 a.m. Oct. 10, 2014 - BusinessWire - BZX
Critical Alerts For Exxon Mobil, Celgene, Verizon, Intercept Pharmaceuticals and Lockheed Martin Released By InvestorsObserver 9:31 a.m. Oct. 8, 2014 - PR Newswire - PRF
Celgene to Present Long-Term Efficacy and Safety Data on Oral OTEZLA® (apremilast) in Plaque Psoriasis and Psoriatic Arthritis at European Academy of Dermatology and Venereology Congress 7:30 a.m. Oct. 7, 2014 - BusinessWire - BZX
Regulatory Approvals, Lawsuits, Positive Study Results, Welfare Initiatives, and Technical Updates - Research Reports on Celgene, Actavis, Bristol-Myers Squibb, UnitedHealth and Vertex 9:20 a.m. Oct. 2, 2014 - PR Newswire - PRF
Celgene Corporation to Announce Third Quarter 2014 Results on October 23, 2014 8:30 a.m. Oct. 1, 2014 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Approved by the U.S. Food and Drug Administration for the Treatment of Patients with Moderate to Severe Plaque Psoriasis 3:18 p.m. Sept. 23, 2014 - BusinessWire - BZX
(0)
(0)Scroll down for more posts ▼